Literature DB >> 27408430

Hyaline-Vascular Type Castleman's Disease, Sarcoidosis, and Crohns Disease.

Arjun Gupta1, Balaji Ayyar1, Hamid Zia2, Weina Chen2, Samar Harris3, Harris V Naina4.   

Abstract

Sarcoidosis and Crohns disease have been associated with increased long term risk of lymphoproliferative disorders, including lymphomas. Newly developed lymphadenopathy in a patient with these disorders should prompt pathological evaluation. Castleman's disease is a lymphoproliferative disorder characterized by enlarged hyperplastic lymph nodes with regressed follicles surrounded by expanded mantle zones of small lymphocytes, and interfollicular vascular proliferation in the hyaline-vascular type. Similar to sarcoidosis and Crohns disease, its etiology is incompletely understood, although immune dysregulation, genetic factors and infectious and environmental factors are thought to play a role in all three diseases. Interleukin-6 is a possible pathological common factor between these three disease processed. Unicentric, hyaline-vascular type Castleman's disease can be treated successfully with complete surgical resection. We report a patient with long history of sarcoidosis and Crohns disease with newly developed lymphadenopathy which was found to be due to Castleman's disease.

Entities:  

Keywords:  Castleman’s disease; Crohns disease; Sarcoidosis; Surgical resection

Year:  2015        PMID: 27408430      PMCID: PMC4925517          DOI: 10.1007/s12288-015-0580-8

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  21 in total

1.  Increased risk for cancer following sarcoidosis.

Authors:  J Askling; J Grunewald; A Eklund; G Hillerdal; A Ekbom
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

Review 2.  Sarcoidosis.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki; Alvin S Teirstein
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

3.  Concomitant Castleman's disease and sarcoidosis.

Authors:  Brenda L Rice; Carol F Farver; Brad Pohlman; Brian B Burkey; Joseph G Parambil
Journal:  Am J Med Sci       Date:  2011-03       Impact factor: 2.378

4.  Multicentric angiofollicular lymph node hyperplasia in ulcerative colitis. A case report.

Authors:  D Browne; E N Barton; K O Barrow; N P Williams; B Hanchard
Journal:  West Indian Med J       Date:  1996-03       Impact factor: 0.171

Review 5.  Surgery in Castleman's disease: a systematic review of 404 published cases.

Authors:  Nadia Talat; Ajay P Belgaumkar; Klaus-Martin Schulte
Journal:  Ann Surg       Date:  2012-04       Impact factor: 12.969

6.  Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Frits van Rhee; Raymond S Wong; Nikhil Munshi; Jean-Francois Rossi; Xiao-Yan Ke; Alexander Fosså; David Simpson; Marcelo Capra; Ting Liu; Ruey Kuen Hsieh; Yeow Tee Goh; Jun Zhu; Seok-Goo Cho; Hanyun Ren; James Cavet; Rajesh Bandekar; Margaret Rothman; Thomas A Puchalski; Manjula Reddy; Helgi van de Velde; Jessica Vermeulen; Corey Casper
Journal:  Lancet Oncol       Date:  2014-07-17       Impact factor: 41.316

7.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.

Authors:  A R Keller; L Hochholzer; B Castleman
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

8.  Risk of haematopoietic cancer in patients with inflammatory bowel disease.

Authors:  J Askling; L Brandt; A Lapidus; P Karlén; M Björkholm; R Löfberg; A Ekbom
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

9.  The clinical behavior of localized and multicentric Castleman disease.

Authors:  J Herrada; F Cabanillas; L Rice; J Manning; W Pugh
Journal:  Ann Intern Med       Date:  1998-04-15       Impact factor: 25.391

10.  Castleman's disease in a patient with celiac disease.

Authors:  Muhammed Hameed Thoufeeq; Michael John Perry
Journal:  Indian J Gastroenterol       Date:  2007 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.